Seagen (SGEN) Stock News

SGEN NYSE

12/14/2023 07:39 AM

News

Pfizer Completes Acquisition of Seagen

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

12/12/2023 06:45 AM

News

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.29%

Tags

-

12/10/2023 07:30 PM

News

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.2%

Tags

12/06/2023 08:15 AM

News

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.01%

Tags

-

11/30/2023 05:00 PM

News

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.23%

Tags

-

11/03/2023 12:00 PM

News

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.1%

Tags

11/02/2023 01:00 PM

News

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.2%

Tags

-

11/01/2023 08:00 AM

News

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.73%

Tags

-

10/22/2023 10:30 AM

News

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.64%

Tags

10/22/2023 10:30 AM

News

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.64%

Tags